| Literature DB >> 26483923 |
Shih-Bin Yeh1, Carlos H Schenck2.
Abstract
OBJECTIVE: To present findings on a series of cases of sporadic nocturnal frontal lobe epilepsy (NFLE), a form of NFLE that is infrequently reported, in contrast to familial (autosomal dominant) NFLE. Both forms of NFLE need to be distinguished from parasomnias, nocturnal temporal lobe epilepsy, and other nocturnal disorders.Entities:
Keywords: Anticonvulsant therapy; Nocturnal frontal lobe epilepsy (sporadic, familial); Nocturnal paroxysmal dystonia; Nocturnal temporal lobe epilepsy; Paroxysmal arousals; Video-polysomnography
Year: 2014 PMID: 26483923 PMCID: PMC4559607 DOI: 10.1016/j.slsci.2014.09.016
Source DB: PubMed Journal: Sleep Sci ISSN: 1984-0063
Clinical data, N=10 patients.
| Patient | Sex | Age of latest visit, yr | Age of initial visit, yr | Age of seizure onset, yr | Duration of seizure history (yrs) | trigger factor | Personal antecedents | Seizure type | Neurological image (MRI) | Positive response to antiepileptic drugs | FLEP score (+ numbers) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 15 | 9 | 5 | 10 | Negative | Negative | NPD | Unremarkable | Yes, oxcarbazepine 600 mg bid and topiramate 25 mg hs | 6 |
| 2 | M | 14 | 8 | 2 | 12 | Protracted exercise | Negative | NPD | Unremarkable | Yes, carbamazepine 200 mg qd & 300 mg hs and topiramate 50 mg bid | 4 |
| 3 | M | 7 | 2 | 1 | 6 | Negative | Negative | NPD | Unremarkable | Yes, carbamazepine 200 mg hs | 5 |
| 4 | F | 12 | 8 | 8 | 4 | Negative | Negative | NPD | Right orbitofrontal lobe cortical dysplasia | Yes, oxcarbazepine 300 mg bid and topiramate 25 mg bid | 6 |
| 5 | F | 41 | 41 | 23 | 18 | Upper respiratory viral infections | Negative | PA | Unremarkable | Yes, carbamazepine 400 mg bid | 4 |
| 6 | M | 7 | 7 | 5 | 2 | Negative | Negative | PA | Unremarkable | Yes, valproate 300 mg bid and levetiracetam 500 mg bid | 3 |
| 7 | F | 33 | 30 | 20 | 13 | Menstrual related | Negative | NPD | Unremarkable | Yes, carbamazepine 200 mg bid or lamotrigine 300 mg hs | 4 |
| 8 | F | 18 | 15 | 6 | 12 | Negative | Negative | NPD | Unremarkable | Yes, acetazolamide 250 mg bid, oxcarbazepine 300 mg hs, and clonazepam 0.5 mg tid | 7 |
Fig. 1Nocturnal PSG (30s epoch) during stage 2 sleep and the emergence of tachypnea following the four limb dystonic posturing. Black solid arrow indicates the event onset time (11:05:03 p.m.), and the event duration persists for 36 sec. EEG montage (channels 12–19) shows with a run of sharp waves during the event episode. The electrooculogram (channel 7–8) indicates no rapid eye movement. The electrocardiogram (channel 11) shows an increase in heart rate during the episode attack. Channels 20–23 represent the nasal/oral airflow, chest respiratory effort, abdomen respiratory effort and O2 saturation, which do not show any sleep apnea or oxygen desaturation, but an increase in respiratory rate beginning with the onset of the episode attack.
Fig. 2Nocturnal PSG (10s epoch) during N2 sleep and the emergence of epileptiform EEG discharge. EEG montage (channels 12–19) shows a run of spike-and-waves during an interictal period. The electrooculogram (channels 7–8) indicates no rapid eye movements. The electrocardiogram (channel 11) is unremarkable during the interictal epileptiform EEG discharge. Channels 20–23 represent the nasal/oral airflow, chest respiratory effort, abdomen respiratory effort and O2 saturation, which do not show any sleep apnea, oxygen desaturation, or tachypnea.